Daly James M 4
4 · MADRIGAL PHARMACEUTICALS, INC. · Filed Jun 18, 2026
Research Summary
AI-generated summary of this filing
Madrigal (MDGL) Director James Daly Receives Equity Awards
What Happened James M. Daly, a director of Madrigal Pharmaceuticals, was awarded equity on 2026-06-17: 454 restricted stock units (RSUs) reported as acquired at $0 and 766 derivative shares reported as acquired at $0 (tied to an option/award). The filing reports no cash purchase — these are compensation awards subject to vesting rather than open‑market buys or sales.
Key Details
- Transaction date(s): 2026-06-17; Form 4 filed 2026-06-18.
- Reported consideration: $0 for both the 454 RSUs and the 766 derivative shares (typical for grants/awards).
- Vesting/conditions: RSUs vest on the earlier of (i) June 17, 2027 or (ii) the issuer’s 2027 annual meeting, contingent on continued service. The 766 derivative/option vests 100% on the same schedule/conditions (see footnotes F1/F2).
- Shares owned after transaction: Not disclosed in the provided filing excerpt.
- Filing timeliness: Filed the day after the transaction; no late‑filing flag indicated in the information provided.
Context These entries are awards/vesting arrangements (compensation) rather than purchases or sales. Such grants compensate service and retention and do not by themselves indicate a personal market buy or sell decision. The derivative entry reflects a grant/option structure that will convert to common shares only if/when vesting conditions are met.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-17+454→ 3,081 total - Award
Stock Option (Right to Buy)
[F2]2026-06-17+766→ 766 totalExercise: $499.86Exp: 2036-06-17→ Common Stock (766 underlying)
Footnotes (2)
- [F1]Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
- [F2]The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.